NCT00899847 · OUTCOME

Incidence of Graft Versus Host Disease (GvHD)

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG · Source last updated 2017-10-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 2 years after the last participant is enrolled.

What was measured

To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting

Analysis population: Due to the significance of the allo-PBSC transplant as a component to the treatment plan, participants who did not receive allo-PBSC are not included.

Groups in this outcome

Autologous-Allogeneic Hematopoietic Stem Cell Transplant

A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	7

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1

denoms

counts
group Id
OG000
value
7
units
Participants

description

To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting

groups

description
A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.
id
OG000
title
Autologous-Allogeneic Hematopoietic Stem Cell Transplant

param Type

COUNT_OF_PARTICIPANTS

population Description

Due to the significance of the allo-PBSC transplant as a component to the treatment plan, participants who did not receive allo-PBSC are not included.

reporting Status

POSTED

time Frame

2 years after the last participant is enrolled.

title

Incidence of Graft Versus Host Disease (GvHD)

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice